Eptifibatide

Identification

Name
Eptifibatide
Accession Number
DB00063  (BTD00063, BIOD00063)
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.

Protein chemical formula
C35H49N11O9S2
Protein average weight
831.962 Da
Sequences
Not Available
Synonyms
  • Integrelin
  • Intrifiban
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eptifibatide InjectionSolution2 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Eptifibatide InjectionSolution0.75 mgIntravenousTeva2013-04-29Not applicableCanada
Eptifibatide InjectionSolution0.75 mgIntravenousFresenius KabiNot applicableNot applicableCanada
Eptifibatide InjectionSolution2 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Eptifibatide InjectionSolution0.75 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Eptifibatide InjectionSolution2 mgIntravenousTeva2013-04-29Not applicableCanada
Eptifibatide InjectionSolution2 mgIntravenousAccord Healthcare LimitedNot applicableNot applicableCanada
Eptifibatide InjectionSolution0.75 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Eptifibatide InjectionSolution2 mgIntravenousFresenius KabiNot applicableNot applicableCanada
Eptifibatide InjectionSolution0.75 mgIntravenousAccord Healthcare LimitedNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EptifibatideInjection, solution2 mg/1mLIntravenousMylan Institutional2018-07-27Not applicableUs
EptifibatideInjection20 mg/10mLIntravenousAurobindo Pharma2015-12-08Not applicableUs
EptifibatideInjection, solution0.75 mg/1mLIntravenousAccord Healthcare Limited2018-04-05Not applicableUs
EptifibatideInjection, solution2 mg/1mLIntravenousAkorn2017-04-18Not applicableUs
EptifibatideInjection20 mg/10mLIntravenousAuro Medics Pharma Llc2015-12-08Not applicableUs
EptifibatideInjection2 mg/1mLIntravenousAmneal Biosciences2016-12-08Not applicableUs
EptifibatideInjection, solution2 mg/1mLIntravenousMylan Institutional2018-07-27Not applicableUs
EptifibatideInjection, solution2 mg/1mLIntravenousSagent Pharmaceuticals2018-07-15Not applicableUs
EptifibatideInjection75 mg/100mLIntravenousAurobindo Pharma2015-12-08Not applicableUs
EptifibatideInjection, solution0.75 mg/1mLIntravenousAkorn2017-04-18Not applicableUs
Categories
UNII
NA8320J834
CAS number
188627-80-7

Pharmacology

Indication

For treatment of myocardial infarction and acute coronary syndrome.

Associated Conditions
Pharmacodynamics

Eptifibatide is an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarus barbouri). It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets.

Mechanism of action

Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.

TargetActionsOrganism
AIntegrin beta-3Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

Approximately 25%

Metabolism

No major metabolites have been detected in human plasma. Deamidated eptifibatide and other, more polar metabolites have been detected in urine.

Route of elimination
Not Available
Half life

Approximately 2.5 hours

Clearance
  • 55 mL/kg/h [patients with coronary artery disease]
Toxicity

Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Eptifibatide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Eptifibatide is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Eptifibatide is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Eptifibatide is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Eptifibatide is combined with Acenocoumarol.
AlaproclateThe risk or severity of hemorrhage can be increased when Alaproclate is combined with Eptifibatide.
AldesleukinThe risk or severity of bleeding can be increased when Eptifibatide is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Eptifibatide is combined with Alemtuzumab.
AloxiprinThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Aloxiprin.
AltretamineThe risk or severity of bleeding can be increased when Eptifibatide is combined with Altretamine.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Aminosalicylic Acid.
Food Interactions
Not Available

References

Synthesis Reference

Guojie Ho, Antoinette Paone, Luciano Forni, Catherine De Tollenaere, Brice Bonnet, Christine Devijver, "Processes for preparing eptifibatide." U.S. Patent US20060036071, issued February 16, 2006.

US20060036071
General References
  1. Nguyen CM, Harrington RA: Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003;3(6):423-36. [PubMed:14728062]
External Links
PubChem Substance
46505459
ChEMBL
CHEMBL1174
Therapeutic Targets Database
DAP000285
PharmGKB
PA449483
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Eptifibatide
ATC Codes
B01AC16 — Eptifibatide
AHFS Codes
  • 20:12.18 — Platelet Aggregation Inhibitors
FDA label
Download (87.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentStrokes1
1, 2TerminatedTreatmentSickle Cell Disorders1
2CompletedTreatmentAcute Coronary Syndromes (ACS)1
2CompletedTreatmentBrain Infarction / Stroke, Ischemic / Strokes1
2CompletedTreatmentBrain Infarction / Strokes1
2CompletedTreatmentCoronary Heart Disease (CHD)1
2CompletedTreatmentStable Angina (SA)1
2CompletedTreatmentStroke, Ischemic1
2RecruitingTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction / Unstable Angina (UA)1
2RecruitingTreatmentStable Angina (SA) / Unstable Angina (UA)1
2TerminatedTreatmentPneumonia1
2TerminatedTreatmentST Elevation Myocardial Infarction (STEMI)1
2Unknown StatusTreatmentAcute Myocardial Infarction (AMI)1
2Unknown StatusTreatmentShock, Septic1
3CompletedSupportive CareCardiovascular Disease (CVD)1
3CompletedTreatmentAcute Coronary Syndromes (ACS)1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Myocardial Ischemia1
3CompletedTreatmentMyocardial Infarction1
3TerminatedTreatmentMyocardial Infarction1
4CompletedTreatmentCoronary Artery Disease / Myocardial Infarction1
4CompletedTreatmentNon ST Elevation Myocardial Infarction1
4TerminatedTreatmentAngioplasty1
4TerminatedTreatmentCoronary Artery Disease1

Pharmacoeconomics

Manufacturers
  • Schering corp
Packagers
  • Assia Chemical Industries Ltd.
  • Patheon Inc.
  • Schering Corp.
  • Schering-Plough Inc.
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
FormRouteStrength
InjectionIntravenous0.75 mg/1mL
InjectionIntravenous2 mg/1mL
InjectionIntravenous20 mg/10mL
InjectionIntravenous200 mg/100mL
InjectionIntravenous75 mg/100mL
Injection, solutionIntravenous0.75 mg/ml
Injection, solutionIntravenous2 mg/ml
Injection, solutionIntravenous0.75 mg/1mL
Injection, solutionIntravenous2 mg/1mL
SolutionIntravenous0.75 mg
SolutionIntravenous2 mg
Prices
Unit descriptionCostUnit
Integrilin 20 mg/10 ml vial12.41USD ml
Integrilin 200 mg/100 ml vial10.74USD ml
Integrilin 75 mg/100 ml vial3.88USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5686570No1994-11-112014-11-11Us
CA2133205No2007-04-172013-04-27Canada
US5807825No1995-09-152015-09-15Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
hydrophobicity-2.3Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Virus receptor activity
Specific Function
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Wil...
Gene Name
ITGB3
Uniprot ID
P05106
Uniprot Name
Integrin beta-3
Molecular Weight
87056.975 Da
References
  1. Amoroso G, van Boven AJ, van Veldhuisen DJ, Tio RA, Balje-Volkers CP, Petronio AS, van Oeveren W: Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol. 2001 Oct;38(4):633-41. [PubMed:11588534]
  2. Schror K, Weber AA: Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis. 2003 Apr;15(2):71-80. [PubMed:14618072]
  3. Fischer TH, Thatte HS, Nichols TC, Bender-Neal DE, Bellinger AD, Vournakis JN: Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis. Biomaterials. 2005 Sep;26(27):5433-43. [PubMed:15860200]
  4. Weber AA, Jacobs C, Meila D, Weber S, Zotz RB, Scharf RE, Kelm M, Strauer BE, Schror K: No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics. 2002 Oct;12(7):581-3. [PubMed:12360110]
  5. Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K: Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther. 2004 Mar;308(3):1002-11. Epub 2003 Nov 14. [PubMed:14617694]
  6. Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B: [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease]. Herz. 2003 Aug;28(5):393-403. [PubMed:12928738]
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2018 20:19